Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
thrombopoietin mimetic + cyclosporin A
- Development stage
- Unknown
- Lead developer
- Assiut University
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous, Intravenous
01
Overview
This is a combination therapy consisting of a thrombopoietin mimetic (such as eltrombopag, romiplostim, or recombinant human thrombopoietin) and cyclosporin A. Thrombopoietin mimetics are agents that stimulate the thrombopoietin receptor (MPL), leading to increased proliferation and differentiation of megakaryocyte progenitors and enhanced platelet production. Cyclosporin A is an immunosuppressive agent that inhibits calcineurin, thereby suppressing T-cell activation. The combination has been investigated primarily for the treatment of aplastic anemia and corticosteroid-resistant immune thrombocytopenia (ITP), where it aims to restore hematopoiesis by both stimulating platelet production and modulating immune-mediated marrow suppression[2][4][5]. Clinical studies have shown improved response rates in refractory ITP and aplastic anemia with this regimen compared to monotherapy[2][3][4].
- Other names
- combination of thrombopoietin mimetic and cyclosporin ATPO-RA + CsA
02
Targets
CN (Calcineurin)
Beyond the preview
Go deeper on thrombopoietin mimetic + cyclosporin A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on thrombopoietin mimetic + cyclosporin A.